Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00410410 · ClinicalTrials.gov registry record · Phase 3
A Study of Abatacept in Patients With Active Ulcerative Colitis
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 591
- Enrollment target
NCT00410410 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 591 participants.
The verdict
NCT00410410, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 591 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active ulcerative colitis in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied
Interventions
- DRUG placebo
- DRUG abatacept
- DRUG abatacept (ABA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 591 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00410410
The ClinicalTrials.gov registry entry for NCT00410410 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 591 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00410410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00410410 about?
NCT00410410 is a clinical study titled "A Study of Abatacept in Patients With Active Ulcerative Colitis". The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active ulcerative colitis in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied
What is the current status of trial NCT00410410?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 591 participants. The study started on 2006-12. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00410410?
The interventions under investigation include: placebo (DRUG), abatacept (DRUG), abatacept (ABA) (DRUG).
Who is sponsoring clinical trial NCT00410410?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.